PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 26847681-6 2016 Mechanistic studies showed that sorafenib significantly increased PS exposure on tumor vasculature; the percentage of PS-positive vessels increased from 19 to 52, 23 to 68, and 30 to 55 % in PLC/PRF/5, C3A, and Huh7 tumors, respectively. Sorafenib 32-41 complement C3 Homo sapiens 202-205